BeOne Medicines is significantly bolstering its presence in the United States with a substantial $300 million investment earmarked for the…
Read More
Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare
Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Sample ages bolster a rising tide doubting a singular 3.9 billion-year-old lunar cataclysm
The long-held theory of a singular, cataclysmic bombardment of the inner solar system, often referred to as the Late Heavy…
Read More
Samsung Biologics to Acquire PolyPeptide Group for SFr1.46 Billion, Expanding Peptide Therapeutics and CDMO Capabilities
Samsung Biologics has announced its intent to acquire PolyPeptide Group, a leading contract development and manufacturing organization (CDMO) specializing in…
Read More
Eli Lilly Acquires AtaiBeckley for $2.8 Billion, Marking Entry into Psychedelic Therapeutics
In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…
Read More
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom
Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More
Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline
Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…
Read MoreYOU MAY HAVE MISSED
